ReviewFrontiers in pharmacology2026
Review of recent advances in chitosan- and hyaluronic-acid-based wound dressings: fabrication, application, and types.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the enormous scale of the global wound dressing market, optimized wound dressings have tremendous market prospects. Chitosan (CS) shows excellent antibacterial and hemostatic activity, and hyaluronic acid (HA) has good biocompatibility, hygroscopicity, and anti-inflammatory activity. For these reasons, both are widely used as wound dressings. In this review, we systematically discuss the characteristics, bioactivities, and commercial wound healing products involving CS and HA. Their limitations, including the low water solubility of CS, instability of HA, and molecular weight (MW)-dependent anti-inflammatory activity of HA, are also outlined. Several chemically modified CS derivatives with enhanced water solubility are discussed. We summarized modified HAs and their stability, finding that mixtures of HAs with different MWs reconcile the opposing effects of low- and high-MW HAs in inflammation and angiogenesis. Moreover, we highlight several types of CS- and HA-based wound dressings, including hydrogels, nanofibers, films, sponges, and scaffolds. Their fabrication and crosslinking methods are introduced in detail, and several limitations of preparation methods and clinical applications are discussed. Finally, we discuss the challenges associated with the clinical translation of wound dressings and possible improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.